Search Videos and More

Showing 25 - 36 of 52 results

Previous| 1... 2 | 3 | 4 ...5 |Next


Clinical Nurse Manager, Rebecca Farrell, MSN, RN, Keeps Calm, Carries On Amidst COVID-19 Pandemic News

Clinical Nurse Manager, Rebecca Farrell, MSN, RN, Keeps Calm, Carries On Amidst COVID-19 Pandemic

As patient care adapted to the restrictions of the COVID-19 pandemic, Farrell continued to ensure that patients had access to cutting-edge care.
Two Studies Provide Answers on Best Approach to Bladder Cancer Treatment News

Two Studies Provide Answers on Best Approach to Bladder Cancer Treatment

Evaluating the current standards of care for cystectomy yielded interesting results on when it is most appropriate.
Fox Chase Offers Ureteral Mitomycin Gel for Low-Grade Upper Tract Urothelial Carcinoma News

Fox Chase Offers Ureteral Mitomycin Gel for Low-Grade Upper Tract Urothelial Carcinoma

Jelmyto provides an alternative treatment option for low-grade UTUC and may spare some patients from nephrectomy. A recent study of the treatment showed a 58% complete response rate.
Immunotherapy for Never Smokers with Non-Small Cell Lung Cancer News

Immunotherapy for Never Smokers with Non-Small Cell Lung Cancer

To further evaluate the use of immunotherapy for these patients with NSCLC, Treat is serving as a primary investigator in a nationwide Phase II, double-arm, randomized clinical trial of treatment-naïve never smokers without the EGFR driver mutation and individuals with EGFR driver mutations for whom standard-of-care therapy with tyrosine kinase inhibitors have failed.
Genitourinary Malignancies in the Time of COVID-19 Symposium

Genitourinary Malignancies in the Time of COVID-19

The COVID-19 pandemic has precipitated many changes in medical practice. View this symposium, where the Fox Chase Cancer Center genitourinary (GU) oncology team will discuss the impact of the pandemic on GU cancer care as well as the latest advances and treatments for GU malignancies.
19th Annual San Antonio Breast Cancer Symposium Symposium

19th Annual San Antonio Breast Cancer Symposium

Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this virtual CME is designed to help medical, radiation and surgical oncologists, gynecologists, radiologists, and primary care physicians translate the data from key presentations from the 2020 San Antonio Breast Cancer Symposium into practice.
Fox Chase Becomes First Cancer Center in the Northeast to Utilize New Surgical Navigation Technology for Breast-Conserving Surgeries News

Fox Chase Becomes First Cancer Center in the Northeast to Utilize New Surgical Navigation Technology for Breast-Conserving Surgeries

Fox Chase Cancer Center is the first cancer center in the Northeast to feature a new tumor marker technology—the EnVisio Surgical Navigation System and SmartClip Soft Tissue Marker technology. This advancement will make breast excisional biopsies and breast-conserving surgeries more precise.
Pulsed Low-Dose-Rate Radiation Offers New Treatment Option for Variety of Solid Tumors News

Pulsed Low-Dose-Rate Radiation Offers New Treatment Option for Variety of Solid Tumors

Clinicians at Fox Chase Cancer Center are exploring how an established radiation technique—pulsed low-dose-rate radiation (PLDR)—might benefit patients with a variety of solid tumors.
Fox Chase Offering Prostate Micro-Ultrasound Technology News

Fox Chase Offering Prostate Micro-Ultrasound Technology

Fox Chase Cancer Center is now offering patients a more convenient and effective method of prostate cancer diagnosis—the ExactVu™ micro-ultrasound system.
CAR T-Cell Therapy Now Available at Fox Chase for Relapsed and Refractory Mantle Cell Lymphoma News

CAR T-Cell Therapy Now Available at Fox Chase for Relapsed and Refractory Mantle Cell Lymphoma

Patients with mantle cell lymphoma treated at Fox Chase Cancer Center will now have access to treatment with brexucabtagene autoleucel (also known as TecartusTM), the first cell-based gene therapy approved by the Food and Drug Administration (FDA).
International Collaboration Finds Ripretinib Significantly Improves Survival for Patients With Advanced Gastrointestinal Stromal Tumors News

International Collaboration Finds Ripretinib Significantly Improves Survival for Patients With Advanced Gastrointestinal Stromal Tumors

Researchers at Fox Chase Cancer Center recently published the results of an international study showing improved survival for patients with advanced gastrointestinal stromal tumors who used ripretinib (Qinlock) when compared with patients taking a placebo.
Urologic Oncology APP and MD Author Book Chapter on Kidney Cancer News

Urologic Oncology APP and MD Author Book Chapter on Kidney Cancer

The clinicians in Fox Chase Cancer Center’s Division of Urology and Urologic Oncology are accustomed to providing patients with specialized care and advanced treatment, but they are also dedicated to sharing their experience and educating other providers. Recently, two members of the group teamed up to write a chapter in Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider.

Showing 25 - 36 of 52 results

Previous| 1... 2 | 3 | 4 ...5 |Next